Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease

Wiener Medizinische Wochenschrift

Volumn 157, Issue 3-4, 2007, Pages 73-78

  Alber, Hannes Franz ^a   Frick, Matthias ^a   Süssenbacher, Alois ^a   Dörler, Jakob ^a   Dichtl, Wolfgang ^a   Stocker, Eva Maria ^a   Pachinger, Otmar ^a   Weidinger, Franz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

c reactive protein; Coronary artery disease; Endothelial function; Soluble intercellular adhesion molecule 1; Statins

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC ACID DERIVATIVE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; E-SELECTIN; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PYRROLES; VASODILATION;

EID: 34247184209     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-007-0377-y     Document Type: Article

References (31)

1. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115
2. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC et al (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26: 1235-1241
3. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE (1994) Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24: 1468-1474
4. Witte DR, Broekmans WM, Kardinaal AF, Klopping-Ketelaars IA, van Poppel G, Bots ML, Kluft C, Princen JM (2003) Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 170: 147-153
5. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, Scopacasa F (2003) Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 38: 374-379
6. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, Weidinger F (1997) Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 129: 111-118
7. Landmesser U, Hornig B, Drexler H (2000) Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 26: 529-537
8. Blum A, Schneider DJ, Sobel BE, Dauerman HL (2004) Endothelial dysfunction and inflammation after percutaneous coronary intervention. Am J Cardiol 94: 1420-1423
9. Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM (2004) C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 25: 1412-1418
10. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM (2004) Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 44: 44-49
11. Granger DN, Vowinkel T, Petnehazy T (2004) Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931
12. Hornig B, Maier V, Drexler H (1996) Physical training improves endothelial function in patients with chronic heart failure. Circulation 93: 210-214
13. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE (1993) Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88: 2149-2155
14. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R (1997) Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 100: 678-684
15. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE (2000) Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 36: 410-416
16. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E (2000) Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36: 617-621
17. Dupuis J, Tardif JC, Cernacek P, Theroux P (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endotheli um) trial. Circulation 99: 3227-3233
18. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G (2001) Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88: 1306-1307
19. Frick M, Alber HF, Hugel H, Schwarzacher SP, Pachinger O, Weidinger F (2002) Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy. Clin Cardiol 25: 291-294
20. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F (2000) Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 86: 207-210
21. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K (2003) Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 169: 283-291
22. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS (2002) Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87: 563-568
23. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235
24. Seljeflot I, Tonstad S, Hjermann I, Arnesen H (2002) Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162: 179-185
25. Fathi R, Haluska B, Short L, Marwick TH (2003) A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention. Am J Med 114: 445-453
26. Weidinger F, Frick M, Alber HF, Ulmer H, Schwarzacher SP, Pachinger O (2002) Association of wall thickness of the brachial artery measured with high-resolution ultrasound with risk factors and coronary artery disease. Am J Cardiol 89: 1025-1029
27. Ridker PM, Rifai N, Lowenthal SP (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103: 1191-1193
28. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ (2001) Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 87: 446-448, A6
29. Halcox JP, Deanfield JE (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109: 1142-1148
30. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135
31. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F (2003) HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 58-63